HighVista Strategies’s Spyre Therapeutics SYRE Stock Holding History

HighVista Strategies’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.91M	Sell	77,807 -68,457	-47%	-$5M	1.57%	16
2026 Q1	$7.38M	Sell	146,264 -41,942	-22%	-$1.58M	2.04%	5
2025 Q4	$6.17M	Sell	188,206 -27,540	-13%	-$720K	1.59%	16
2025 Q3	$3.62M	Buy	215,746 +102,941	+91%	+$1.68M	0.89%	30
2025 Q2	$1.69M	Buy	112,805 +17,646	+19%	+$261K	0.62%	57
2025 Q1	$1.54M	Hold	95,159	–	–	0.59%	66
2024 Q4	$2.22M	Sell	95,159 -10,192	-10%	-$299K	0.82%	36
2024 Q3	$3.1M	Sell	105,351 -8,199	-7%	-$228K	1.07%	27
2024 Q2	$2.67M	Sell	113,550 -40,831	-26%	-$1.38M	0.98%	29
2024 Q1	$5.86M	Sell	154,381 -423,235	-73%	-$12.3M	2.09%	3
2023 Q4	$12.4M	Buy	+577,616	New	+$7.96M	4.51%	2
2021 Q4	–	Sell	-525	Closed	-$105K	–	114
2021 Q3	$105K	Buy	+525	New	+$91.8K	0.07%	93

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

HighVista Strategies's SYRE Position: Q2 2026 in Review

HighVista Strategies reduced its Spyre Therapeutics (SYRE) stake by 47% in Q2 2026, selling an estimated $5M and leaving 77,807 shares worth $6.91M. The position accounts for 1.57% of the portfolio, ranked #16.

HighVista Strategies first reported a position in SYRE in Q3 2021 and has held it in 12 quarters since. The position peaked at $12.4M in Q4 2023. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

HighVista Strategies held 77,807 shares of Spyre Therapeutics worth $6.91M as of Q2 2026.
HighVista Strategies sold 68,457 Spyre Therapeutics shares in Q2 2026, an estimated $5M.
Spyre Therapeutics made up 1.57% of HighVista Strategies's portfolio in Q2 2026, its #16 holding.
HighVista Strategies first reported a position in Spyre Therapeutics in Q3 2021 and has held it in 12 quarters since.
HighVista Strategies's Spyre Therapeutics position peaked at $12.4M in Q4 2023.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.